A5025595346- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA Research and Splicing
- RNA modifications and cancer
- Mitochondrial Function and Pathology
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Genetics and Neurodevelopmental Disorders
- Histiocytic Disorders and Treatments
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Cancer-related gene regulation
- Melanoma and MAPK Pathways
- RNA and protein synthesis mechanisms
- Mast cells and histamine
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Nuclear Structure and Function
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Pancreatic function and diabetes
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2015-2025
Cornell University
2014-2024
Cincinnati Children's Hospital Medical Center
2023
NewYork–Presbyterian Hospital
2012-2023
New York Hospital Queens
2012-2023
Presbyterian Hospital
2023
New York Proton Center
2022
Memorial Hospital
2022
Université Paris-Saclay
2021
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in phase 3 trial treatment for AML.We performed mutational analysis 18 genes 398 patients younger than 60 years age who had AML were randomly assigned receive induction therapy high-dose or standard-dose daunorubicin. We validated our findings an independent set 104 patients.We at least...
Myelodysplastic syndromes are clinically heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood cytopenias, and a risk of progression to acute myeloid leukemia. Somatic mutations may influence the clinical phenotype but not included in current prognostic scoring systems.
ERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRAF mutants evade feedback inhibition of RAS either two mechanisms. V600 are activated monomers when activity low; all other activating function as constitutive RAS-independent dimers. inhibitors effectively inhibit mutant monomers, but not dimers; their binding to one site in the dimer significantly reduces affinity for second. Tumors with non-V600E insensitive these drugs, increased expression V600E...
Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans (non-LCH), respectively. The discovery BRAF(V600E) mutations approximately 50% these patients provided the first molecular therapeutic target histiocytosis. However, recurrent driving majority with BRAF(V600E)-wild-type non-LCH unknown, cooperating non-MAP kinase pathways undefined for...
A subset of patients with myelodysplastic syndromes (MDS) who are predicted to have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) demonstrate more aggressive and shorter overall survival than expected. The identification greater-than-predicted prognostic risk could influence selection therapy improve care MDS.We performed an independent validation MD Anderson Lower-Risk (LR-PSS) in a cohort 288 low- or intermediate-1 IPSS MDS examined bone marrow samples...
De-ubiquitinating enzyme BAP1 is mutated in a hereditary cancer syndrome with increased risk of mesothelioma and uveal melanoma. Somatic mutations occur various malignancies. We show that mouse Bap1 gene deletion lethal during embryogenesis, but systemic or hematopoietic-restricted adults recapitulates features human myelodysplastic (MDS). Knockin mice expressing 3xFlag tag revealed interacts host cell factor-1 (HCF-1), O-linked N-acetylglucosamine transferase (OGT), the polycomb group...